Selective anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) have transformed ALK-rearranged non-small cell lung cancer therapy (NSCLC). The gene discussed is ALK; the disease is non-small cell lung carcinoma.